These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 26646998)
1. Utility of 11C-Methionine and 18F-FDG PET/CT in Patients With Functioning Pituitary Adenomas. Feng Z; He D; Mao Z; Wang Z; Zhu Y; Zhang X; Wang H Clin Nucl Med; 2016 Mar; 41(3):e130-4. PubMed ID: 26646998 [TBL] [Abstract][Full Text] [Related]
2. High-resolution(18)F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease. Chittiboina P; Montgomery BK; Millo C; Herscovitch P; Lonser RR J Neurosurg; 2015 Apr; 122(4):791-7. PubMed ID: 25479121 [TBL] [Abstract][Full Text] [Related]
3. PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study. Wang H; Hou B; Lu L; Feng M; Zang J; Yao S; Feng F; Wang R; Li F; Zhu Z J Nucl Med; 2018 Mar; 59(3):523-528. PubMed ID: 28775202 [TBL] [Abstract][Full Text] [Related]
4. Utility of Wang Z; Mao Z; Zhang X; He D; Wang X; Du Q; Xiao Z; Zhu D; Zhu Y; Wang H Acad Radiol; 2019 Sep; 26(9):1222-1228. PubMed ID: 30318288 [TBL] [Abstract][Full Text] [Related]
5. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas. Li DL; Xu YK; Wang QS; Wu HB; Li HS Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472 [TBL] [Abstract][Full Text] [Related]
6. Analysis of 18F-fluorodeoxyglucose positron emission tomography findings in patients with pituitary lesions. Seok H; Lee EY; Choe EY; Yang WI; Kim JY; Shin DY; Cho HJ; Kim TS; Yun MJ; Lee JD; Lee EJ; Lim SK; Rhee Y Korean J Intern Med; 2013 Jan; 28(1):81-8. PubMed ID: 23346000 [TBL] [Abstract][Full Text] [Related]
7. Usefulness of composite methionine-positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma. Ikeda H; Abe T; Watanabe K J Neurosurg; 2010 Apr; 112(4):750-5. PubMed ID: 19698042 [TBL] [Abstract][Full Text] [Related]
8. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging]. Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892 [TBL] [Abstract][Full Text] [Related]
9. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma. Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383 [TBL] [Abstract][Full Text] [Related]
10. PET/CT findings for tumors in the base of the skull: comparison of 18 F-FDG with 11 C-methionine. Tomura N; Mizuno Y; Saginoya T Acta Radiol; 2016 Mar; 57(3):325-32. PubMed ID: 25795702 [TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of coregistered 11C-methionine positron emission tomography/3-T magnetic resonance imaging at the follow-up of acromegaly. Rodriguez-Barcelo S; Gutierrez-Cardo A; Dominguez-Paez M; Medina-Imbroda J; Romero-Moreno L; Arraez-Sanchez M World Neurosurg; 2014; 82(3-4):468-73. PubMed ID: 24239736 [TBL] [Abstract][Full Text] [Related]
12. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Shiiba M; Ishihara K; Kimura G; Kuwako T; Yoshihara H; Sato H; Kondo Y; Tsuchiya S; Kumita S Ann Nucl Med; 2012 Feb; 26(2):138-45. PubMed ID: 22069194 [TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET rarely provides additional information to 11C-methionine PET imaging in hyperparathyroidism. Chicklore S; Schulte KM; Talat N; Hubbard JG; O'Doherty M; Cook GJ Clin Nucl Med; 2014 Mar; 39(3):237-42. PubMed ID: 24445273 [TBL] [Abstract][Full Text] [Related]
15. The pituitary in nuclear medicine imaging. Iglesias P; Cardona J; Díez JJ Eur J Intern Med; 2019 Oct; 68():6-12. PubMed ID: 31519379 [TBL] [Abstract][Full Text] [Related]
16. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging. Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400 [TBL] [Abstract][Full Text] [Related]
17. Pituitary adenomas can appear as hypermetabolic lesions in (18) F-FDG PET imaging. Ryu SI; Tafti BA; Skirboll SL J Neuroimaging; 2010 Oct; 20(4):393-6. PubMed ID: 19453834 [TBL] [Abstract][Full Text] [Related]
18. Incidental pituitary uptake on whole-body 18F-FDG PET/CT: a multicentre study. Jeong SY; Lee SW; Lee HJ; Kang S; Seo JH; Chun KA; Cho IH; Won KS; Zeon SK; Ahn BC; Lee J Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2334-43. PubMed ID: 20661556 [TBL] [Abstract][Full Text] [Related]
19. Clinical value of ¹¹C-methionine PET/CT in patients with plasma cell malignancy: comparison with ¹⁸F-FDG PET/CT. Nakamoto Y; Kurihara K; Nishizawa M; Yamashita K; Nakatani K; Kondo T; Takaori-Kondo A; Togashi K Eur J Nucl Med Mol Imaging; 2013 May; 40(5):708-15. PubMed ID: 23340595 [TBL] [Abstract][Full Text] [Related]
20. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]